カテゴリ： GlobalData, ドイツ, 企業調査

Bayer AG (BAYN)-医療機器分野：企業M&A・提携分析

◆英語タイトル：Bayer AG (BAYN) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA8011424
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月22日
◆ページ数：95
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：ドイツ
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Bayer AG (Bayer) carries out the research, development, production and commercialization of products in the areas of human and animal health care, and agriculture. It provides pharmaceuticals for cardiology, women’s healthcare, oncology, hematology, ophthalmology, infection and other indications. The company’s product portfolio includes prescription products, specialty therapeutics, animal health care products, diagnostic imaging equipment, nonprescription (over-the-counter – OTC) products, seeds, crop protection solutions, nonagricultural pest control solutions, and high-tech polymer materials. Bayer markets its healthcare and crop protection products principally through wholesalers, pharmacies, hospitals and retailers. It operates through a network of subsidiaries in Asia-Pacific, Europe, the US, and other markets such as Latin America, Africa and the Middle East. Bayer is headquartered in Leverkusen, Germany.

Bayer AG (BAYN) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Bayer AG, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Bayer AG, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Bayer AG, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Bayer AG, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Bayer AG, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Bayer AG, Medical Equipment, Deal Details 12
Partnerships 12
Bayer Enters into Licensing Agreement with DelSiTech 12
ChromoTek Enters Into Licensing Agreement With Bayer For Cell Cycle Chromobody Technology 13
Icagen Enters into Agreement with Bayer 14
Bayer Enters into Co-Development Agreement with Leica Biosystems 15
T2 Biosystems Enters into R&D Agreement with Bayer 16
Genedata Enters into Co-Development Agreement with Bayer Pharma 17
Orion Enters into Agreement with Bayer for Prostate Cancer Treatment 18
Ventana Extends Co-Development Agreement With Bayer Pharma 19
Bayer Yakuhin Enters Into Distribution Agreement With Femasys For FemVue Saline-Air Device 20
Ventana Medical Systems Enters Into Co-Development Agreement With Bayer Pharma 21
Bayer Vital Signs Agreement With Vital Images 22
Debt Offering 23
Bayer Raises USD4.3 Billion in Private Placement of Convertible Notes due 2019 23
Bayer Raises USD1.4 Billion in Public Offering of 2.375% Hybrid Bonds Due 2075 24
Bayer Prices 1.25% Bonds Due 2023 for USD623.5 Million 25
Bayer Raises USD2.38 Billion in Public Offering of 3% Bonds Due 2075 26
Bayer Raises USD2 Billion in Public Offering of 3.75% Bonds Due 2074 28
Bayer Raises USD677.3 Million in Public Offering of Notes Due 2016 30
Bayer Raises USD1.02 Billion in Public Offering of 1.125% Notes Due 2018 31
Bayer Raises USD1.02 Billion in Public Offering of 1.875% Bonds Due 2021 32
Bayer Completes Public Offering Of Notes Due 2019 For US$102 Million 33
Bayer Completes Public Offering Of Notes Due 2016 For US$259 Million 34
Bayer Holding Completes Public Offering Of 0.82% Corporate Bonds Due 2017 For US$363 Million 35
Asset Transactions 36
Bayer May Sell Radiology Business 36
Panasonic Healthcare Acquires Diabetes Care Business from Bayer for USD1.15 Billion 37
Boston Scientific Acquires Vascular Catheter Business of Bayer for USD414 Million 38
Polymer Technology Systems Acquires A1CNow From Bayer Diabetes Care 39
Piramal Healthcare Completes Acquisition Of Molecular Imaging Development Portfolio Of Bayer Pharma 40
Acquisition 41
Bayer May Acquire Sirtex Medical 41
Bayer Completes Acquisition Of 96.4% Stake In Conceptus For US$1.1 Billion 42
MEDRAD Completes Acquisition Of Pathway Medical Technologies For US$125 Million 44
Bayer AG – Key Competitors 46
Bayer AG – Key Employees 47
Bayer AG – Locations And Subsidiaries 50
Head Office 50
Other Locations & Subsidiaries 50
Joint Venture 59
Recent Developments 60
Strategy And Business Planning 60
Sep 20, 2016: Bayer sets ambitious growth and earnings aspirations 60
Financial Announcements 62
Oct 26, 2017: Bayer: Sales and earnings increased 62
Apr 27, 2017: Strong start to the year for Bayer 67
Apr 26, 2016: Bayer Announces Interim report for the first quarter of 2016 70
Corporate Communications 72
Nov 15, 2017: Heiko Schipper to join Bayer Board of Management and head Consumer Health Division 72
Nov 15, 2017: Heiko Schipper is the new CEO and Head of the Consumer Health Division at Bayer 73
Oct 19, 2017: Bayer Appoints Jennifer Brendel to Vice President, Head of U.S. Consumer Health Communications 74
Sep 22, 2017: Bayer Appoints Dr. Sharon James Head of Global Innovation & Development for Consumer Health 75
Sep 12, 2017: Wolfgang Nickl to be new Chief Financial Officer at Bayer 76
Sep 07, 2017: Bayer again listed in the Dow Jones Sustainability World Index 77
Jun 05, 2017: Bayer Expands Oncology Organization with Two New Leadership Team Appointments 78
May 02, 2017: Bayer Appoints Bhavesh Ashar to Lead U.S. Oncology Business 79
Apr 27, 2017: Supervisory Board of Bayer extends service contract of CFO Johannes Dietsch to the end of May 2018 80
Jan 17, 2017: Dr. Carsten Brunn to Lead Bayer’s Pharmaceuticals Business in the Americas Region 81
Apr 25, 2016: 2016 Otto Bayer Award goes to Professor Dr. Dirk Trauner 82
Mar 23, 2016: Dr. Michael Preuss to be new head of Communications at Bayer 83
Feb 24, 2016: Werner Baumann to succeed Dr. Marijn Dekkers as Chairman of the Board of Management of Bayer AG 84
Legal and Regulatory 85
Aug 22, 2017: Bayer will continue to work constructively with the European Commission 85
Government and Public Interest 86
Feb 22, 2017: Another record year for Bayer – good progress with the acquisition of Monsanto 86
Product News 90
02/29/2016: FDA takes additional action to better understand safety of Essure, inform patients of potential risks 90
Other Significant Developments 92
Jul 27, 2016: Bayer raises sales and earnings 92
Appendix 95
Methodology 95
About GlobalData 95
Contact Us 95
Disclaimer 95

List of Tables
Bayer AG, Medical Equipment, Key Facts, 2016 2
Bayer AG, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Bayer AG, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Bayer AG, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Bayer AG, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Bayer AG, Deals By Market, 2011 to YTD 2017 9
Bayer AG, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Bayer Enters into Licensing Agreement with DelSiTech 12
ChromoTek Enters Into Licensing Agreement With Bayer For Cell Cycle Chromobody Technology 13
Icagen Enters into Agreement with Bayer 14
Bayer Enters into Co-Development Agreement with Leica Biosystems 15
T2 Biosystems Enters into R&D Agreement with Bayer 16
Genedata Enters into Co-Development Agreement with Bayer Pharma 17
Orion Enters into Agreement with Bayer for Prostate Cancer Treatment 18
Ventana Extends Co-Development Agreement With Bayer Pharma 19
Bayer Yakuhin Enters Into Distribution Agreement With Femasys For FemVue Saline-Air Device 20
Ventana Medical Systems Enters Into Co-Development Agreement With Bayer Pharma 21
Bayer Vital Signs Agreement With Vital Images 22
Bayer Raises USD4.3 Billion in Private Placement of Convertible Notes due 2019 23
Bayer Raises USD1.4 Billion in Public Offering of 2.375% Hybrid Bonds Due 2075 24
Bayer Prices 1.25% Bonds Due 2023 for USD623.5 Million 25
Bayer Raises USD2.38 Billion in Public Offering of 3% Bonds Due 2075 26
Bayer Raises USD2 Billion in Public Offering of 3.75% Bonds Due 2074 28
Bayer Raises USD677.3 Million in Public Offering of Notes Due 2016 30
Bayer Raises USD1.02 Billion in Public Offering of 1.125% Notes Due 2018 31
Bayer Raises USD1.02 Billion in Public Offering of 1.875% Bonds Due 2021 32
Bayer Completes Public Offering Of Notes Due 2019 For US$102 Million 33
Bayer Completes Public Offering Of Notes Due 2016 For US$259 Million 34
Bayer Holding Completes Public Offering Of 0.82% Corporate Bonds Due 2017 For US$363 Million 35
Bayer May Sell Radiology Business 36
Panasonic Healthcare Acquires Diabetes Care Business from Bayer for USD1.15 Billion 37
Boston Scientific Acquires Vascular Catheter Business of Bayer for USD414 Million 38
Polymer Technology Systems Acquires A1CNow From Bayer Diabetes Care 39
Piramal Healthcare Completes Acquisition Of Molecular Imaging Development Portfolio Of Bayer Pharma 40
Bayer May Acquire Sirtex Medical 41
Bayer Completes Acquisition Of 96.4% Stake In Conceptus For US$1.1 Billion 42
MEDRAD Completes Acquisition Of Pathway Medical Technologies For US$125 Million 44
Bayer AG, Key Competitors 46
Bayer AG, Key Employees 47
Bayer AG, Subsidiaries 50
Bayer AG, Joint Venture 59

★海外企業調査レポート[Bayer AG (BAYN)-医療機器分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Symbiotec Pharmalab Ltd-製薬・医療分野：企業M&A・提携分析
    Summary Symbiotec Pharmalab Ltd (Symbiotec) is a medical laboratory that manufactures active pharmaceutical ingredients. The laboratory develops, produces and markets research-based cortico steroids and steroid-hormone APIs. Its cortico-steroids APIs include clobetasol propionate, betamethasone dipr …
  • Canadian Solar Inc (CSIQ)：電力：M&Aディール及び事業提携情報
    Summary Canadian Solar Inc (Canadian Solar) is a solar power company. It designs, develops, and manufactures solar ingots, wafers, modules, cells, and other solar power products. The company’s products include a range of solar modules for use in residential, commercial and industrial solar power gen …
  • Alnylam Pharmaceuticals Inc (ALNY)：製薬・医療：M&Aディール及び事業提携情報
    Summary Alnylam Pharmaceuticals Inc (Alnylam) is a biopharmaceutical company which discovers, develops and commercializes therapeutics based on Ribo Nucleic Acid interference (RNAi). The company offers a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines, hepatic i …
  • Real Matters Inc (REAL)：企業の財務・戦略的SWOT分析
    Real Matters Inc (REAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • KOSE Corp：企業の戦略・SWOT・財務情報
    KOSE Corp - Strategy, SWOT and Corporate Finance Report Summary KOSE Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Ramaco Resources Inc. (METC)：企業の財務・戦略的SWOT分析
    Ramaco Resources Inc. (METC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Telecom Argentina S.A.：企業の戦略・SWOT・財務分析
    Telecom Argentina S.A. - Strategy, SWOT and Corporate Finance Report Summary Telecom Argentina S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • VLP Therapeutics LLC：製薬・医療：M&Aディール及び事業提携情報
    Summary VLP Therapeutics LLC (VLP) is a biopharmaceutical company that develops therapeutic vaccines and next generation of targeted antibody agents to address global unmet medical needs. The company offers product such as vaccines for the treatment of cancer types such as breast, lung, prostate can …
  • Ezion Holdings Limited：企業のM&A・事業提携・投資動向
    Ezion Holdings Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Ezion Holdings Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Pacific Edge Ltd (PEB)：企業の財務・戦略的SWOT分析
    Summary Pacific Edge Ltd (PEB) is a diagnostics company that develops, discovers, and commercializes diagnostic tests for the early detection and monitoring of cancer. The company provides lead product such as Cxbladder, a non-invasive laboratory test for the detection of bladder cancer. It also dev …
  • Euro India Fresh Foods Ltd (EIFFL)：企業の財務・戦略的SWOT分析
    Euro India Fresh Foods Ltd (EIFFL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Agios Pharmaceuticals Inc (AGIO)：製薬・医療：M&Aディール及び事業提携情報
    Summary Agios Pharmaceuticals Inc (Agios) is a biopharmaceutical company that focuses on the discovery and development of investigational medicines for the treatment of cancer and rare genetic metabolic disorders. The company’s products include IDHIFA, an oral targeted inhibitor of the mutated IDH2 …
  • Vision RT Ltd：企業の戦略的SWOT分析
    Vision RT Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Genedata AG-医療機器分野：企業M&A・提携分析
    Summary Genedata AG (Genedata) is a healthcare technology company that transforms data into software solutions. The company delivers enterprise solutions for data analytics that streamline research and development workflows and improve research productivity. Its products include genedata biologics, …
  • Sempra U.S. Gas & Power LLC-石油・ガス分野：企業M&A・提携分析
    Summary Sempra U.S. Gas & Power, LLC (Sempra US), a subsidiary of Sempra Energy, an energy solution provider, is a clean power solutions developer. It develops, designs, constructs and operates renewable energy and natural gas solutions, with a focus on zero and low emission fuels. The company owns …
  • Sumitomo Forestry Co Ltd：企業の戦略・SWOT・財務分析
    Sumitomo Forestry Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Forestry Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Sojitz Corporation：企業の戦略・SWOT・財務分析
    Sojitz Corporation - Strategy, SWOT and Corporate Finance Report Summary Sojitz Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Ceska Sprava Socialniho Zabezpeceni：企業の戦略的SWOT分析
    Ceska Sprava Socialniho Zabezpeceni - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Hino Motors Ltd (7205)：企業の財務・戦略的SWOT分析
    Hino Motors Ltd (7205) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Fate Therapeutics Inc (FATE)：製薬・医療：M&Aディール及び事業提携情報
    Summary Fate Therapeutics Inc (Fate Therapeutics) is a biopharmaceutical company that develops programmed cellular therapies for cancer and immune disorders. The company’s pipeline product candidates include cellular immunotherapy pipeline, immuno-oncology candidates, and immuno-regulatory candidate …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆